Feasibility and acceptance of simultaneous amyloid PET/MRI
Purpose Established Alzheimer’s disease (AD) biomarker concepts classify into amyloid pathology and neuronal injury biomarkers, while recent alternative concepts classify into diagnostic and progression AD biomarkers. However, combined amyloid positron emission tomography/magnetic resonance imaging...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2016-11, Vol.43 (12), p.2236-2243 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2243 |
|---|---|
| container_issue | 12 |
| container_start_page | 2236 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 43 |
| creator | Schütz, Lisa Lobsien, Donald Fritzsch, Dominik Tiepolt, Solveig Werner, Peter Schroeter, Matthias L. Berrouschot, Jörg Saur, Dorothee Hesse, Swen Jochimsen, Thies Rullmann, Michael Sattler, Bernhard Patt, Marianne Gertz, Hermann-Josef Villringer, Arno Claßen, Joseph Hoffmann, Karl-Titus Sabri, Osama Barthel, Henryk |
| description | Purpose
Established Alzheimer’s disease (AD) biomarker concepts classify into amyloid pathology and neuronal injury biomarkers, while recent alternative concepts classify into diagnostic and progression AD biomarkers. However, combined amyloid positron emission tomography/magnetic resonance imaging (PET/MRI) offers the chance to obtain both biomarker category read-outs within one imaging session, with increased patient as well as referrer convenience. The aim of this pilot study was to investigate this matter for the first time.
Methods
100 subjects (age 70 ± 10 yrs, 46 female), n = 51 with clinically defined mild cognitive impairment (MCI), n = 44 with possible/probable AD dementia, and n = 5 with frontotemporal lobe degeneration, underwent simultaneous [
18
F]florbetaben or [
11
C]PIB PET/MRI (3 Tesla Siemens mMR). Brain amyloid load, mesial temporal lobe atrophy (MTLA) by means of the Scheltens scale, and other morphological brain pathologies were scored by respective experts. The patients/caregivers as well as the referrers were asked to assess on a five-point scale the convenience related to the one-stop-shop PET and MRI approach.
Results
In three subjects, MRI revealed temporal lobe abnormalities other than MTLA. According to the National Institute on Aging-Alzheimer’s Association classification, the combined amyloid-beta PET/MRI evaluation resulted in 31 %, 45 %, and 24 % of the MCI subjects being categorized as “MCI-unlikely due to AD”, “MCI due to AD-intermediate likelihood”, and “MCI due to AD-high likelihood”, respectively. 50 % of the probable AD dementia patients were categorized as “High level of evidence of AD pathophysiological process”, and 56 % of the possible AD dementia patients as “Possible AD dementia - with evidence of AD pathophysiological process”. With regard to the International Working Group 2 classification, 36 subjects had both positive diagnostic and progression biomarkers. The patient/caregiver survey revealed a gain of convenience in 88 % of responders as compared to a theoretically separate PET and MR imaging. In the referrer survey, an influence of the combined amyloid-beta PET/MRI on the final diagnosis was reported by 82 % of responders, with a referrer acceptance score of 3.7 ± 1.0 on a 5-point scale.
Conclusion
Simultaneous amyloid PET/MRI is feasible and provides imaging biomarkers of all categories which are able to supplement the clinical diagnosis of MCI due to AD and that of AD dementia. Further, patient and refe |
| doi_str_mv | 10.1007/s00259-016-3462-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1827925698</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826729787</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-c7404c0612e8eefe2b61cf1e445017e312150a20bf6852aafb55d144badae3d53</originalsourceid><addsrcrecordid>eNqNkV1LwzAUhoMobn78AG-k4I03dSdpPlrvZGw6mCgyr0OankpHP2azwvbvzegcIgheJSHPec8570vIFYU7CqBGDoCJJAQqw4hLFm6OyJBKmoQK4uT4cFcwIGfOLQFozOLklAyY4pGIpBqS-ykaV6RFWay3gamzwFiLq7WpLQZNHrii6kr_wqZzgam2ZVNkwetkMXp-m12Qk9yUDi_35zl5n04W46dw_vI4Gz_MQ8sVXYdWceAWJGUYI-bIUkltTpFzAVRhRBkVYBikuYwFMyZPhcgo56nJDEaZiM7Jba-7apvPDt1aV4WzWJb9WNovpRImZBL_B5WKJSpWHr35hS6brq39IjvKmyM86CnaU7ZtnGsx16u2qEy71RT0LgPdZ6B9BnqXgd74muu9cpdWmB0qvk33AOsB57_qD2x_tP5T9QutsI_S</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1825365729</pqid></control><display><type>article</type><title>Feasibility and acceptance of simultaneous amyloid PET/MRI</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Schütz, Lisa ; Lobsien, Donald ; Fritzsch, Dominik ; Tiepolt, Solveig ; Werner, Peter ; Schroeter, Matthias L. ; Berrouschot, Jörg ; Saur, Dorothee ; Hesse, Swen ; Jochimsen, Thies ; Rullmann, Michael ; Sattler, Bernhard ; Patt, Marianne ; Gertz, Hermann-Josef ; Villringer, Arno ; Claßen, Joseph ; Hoffmann, Karl-Titus ; Sabri, Osama ; Barthel, Henryk</creator><creatorcontrib>Schütz, Lisa ; Lobsien, Donald ; Fritzsch, Dominik ; Tiepolt, Solveig ; Werner, Peter ; Schroeter, Matthias L. ; Berrouschot, Jörg ; Saur, Dorothee ; Hesse, Swen ; Jochimsen, Thies ; Rullmann, Michael ; Sattler, Bernhard ; Patt, Marianne ; Gertz, Hermann-Josef ; Villringer, Arno ; Claßen, Joseph ; Hoffmann, Karl-Titus ; Sabri, Osama ; Barthel, Henryk</creatorcontrib><description>Purpose
Established Alzheimer’s disease (AD) biomarker concepts classify into amyloid pathology and neuronal injury biomarkers, while recent alternative concepts classify into diagnostic and progression AD biomarkers. However, combined amyloid positron emission tomography/magnetic resonance imaging (PET/MRI) offers the chance to obtain both biomarker category read-outs within one imaging session, with increased patient as well as referrer convenience. The aim of this pilot study was to investigate this matter for the first time.
Methods
100 subjects (age 70 ± 10 yrs, 46 female), n = 51 with clinically defined mild cognitive impairment (MCI), n = 44 with possible/probable AD dementia, and n = 5 with frontotemporal lobe degeneration, underwent simultaneous [
18
F]florbetaben or [
11
C]PIB PET/MRI (3 Tesla Siemens mMR). Brain amyloid load, mesial temporal lobe atrophy (MTLA) by means of the Scheltens scale, and other morphological brain pathologies were scored by respective experts. The patients/caregivers as well as the referrers were asked to assess on a five-point scale the convenience related to the one-stop-shop PET and MRI approach.
Results
In three subjects, MRI revealed temporal lobe abnormalities other than MTLA. According to the National Institute on Aging-Alzheimer’s Association classification, the combined amyloid-beta PET/MRI evaluation resulted in 31 %, 45 %, and 24 % of the MCI subjects being categorized as “MCI-unlikely due to AD”, “MCI due to AD-intermediate likelihood”, and “MCI due to AD-high likelihood”, respectively. 50 % of the probable AD dementia patients were categorized as “High level of evidence of AD pathophysiological process”, and 56 % of the possible AD dementia patients as “Possible AD dementia - with evidence of AD pathophysiological process”. With regard to the International Working Group 2 classification, 36 subjects had both positive diagnostic and progression biomarkers. The patient/caregiver survey revealed a gain of convenience in 88 % of responders as compared to a theoretically separate PET and MR imaging. In the referrer survey, an influence of the combined amyloid-beta PET/MRI on the final diagnosis was reported by 82 % of responders, with a referrer acceptance score of 3.7 ± 1.0 on a 5-point scale.
Conclusion
Simultaneous amyloid PET/MRI is feasible and provides imaging biomarkers of all categories which are able to supplement the clinical diagnosis of MCI due to AD and that of AD dementia. Further, patient and referrer convenience is improved by this one-stop-shop imaging approach.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-016-3462-x</identifier><identifier>PMID: 27435367</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Alzheimer Disease - diagnostic imaging ; Alzheimer Disease - metabolism ; Alzheimer's disease ; Amyloid - metabolism ; Attitude of Health Personnel ; Biomarkers - metabolism ; Cardiology ; Cognitive Dysfunction - diagnostic imaging ; Cognitive Dysfunction - metabolism ; Feasibility Studies ; Female ; Humans ; Image Enhancement - methods ; Imaging ; Magnetic Resonance Imaging - methods ; Male ; Medical imaging ; Medicine ; Medicine & Public Health ; Molecular Imaging - methods ; Multimodal Imaging - methods ; Nuclear Medicine ; Oncology ; Original Article ; Orthopedics ; Pathology ; Patient Acceptance of Health Care ; Positron-Emission Tomography - methods ; Radiology ; Reproducibility of Results ; Sensitivity and Specificity</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2016-11, Vol.43 (12), p.2236-2243</ispartof><rights>Springer-Verlag Berlin Heidelberg 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-c7404c0612e8eefe2b61cf1e445017e312150a20bf6852aafb55d144badae3d53</citedby><cites>FETCH-LOGICAL-c471t-c7404c0612e8eefe2b61cf1e445017e312150a20bf6852aafb55d144badae3d53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-016-3462-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-016-3462-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27435367$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schütz, Lisa</creatorcontrib><creatorcontrib>Lobsien, Donald</creatorcontrib><creatorcontrib>Fritzsch, Dominik</creatorcontrib><creatorcontrib>Tiepolt, Solveig</creatorcontrib><creatorcontrib>Werner, Peter</creatorcontrib><creatorcontrib>Schroeter, Matthias L.</creatorcontrib><creatorcontrib>Berrouschot, Jörg</creatorcontrib><creatorcontrib>Saur, Dorothee</creatorcontrib><creatorcontrib>Hesse, Swen</creatorcontrib><creatorcontrib>Jochimsen, Thies</creatorcontrib><creatorcontrib>Rullmann, Michael</creatorcontrib><creatorcontrib>Sattler, Bernhard</creatorcontrib><creatorcontrib>Patt, Marianne</creatorcontrib><creatorcontrib>Gertz, Hermann-Josef</creatorcontrib><creatorcontrib>Villringer, Arno</creatorcontrib><creatorcontrib>Claßen, Joseph</creatorcontrib><creatorcontrib>Hoffmann, Karl-Titus</creatorcontrib><creatorcontrib>Sabri, Osama</creatorcontrib><creatorcontrib>Barthel, Henryk</creatorcontrib><title>Feasibility and acceptance of simultaneous amyloid PET/MRI</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
Established Alzheimer’s disease (AD) biomarker concepts classify into amyloid pathology and neuronal injury biomarkers, while recent alternative concepts classify into diagnostic and progression AD biomarkers. However, combined amyloid positron emission tomography/magnetic resonance imaging (PET/MRI) offers the chance to obtain both biomarker category read-outs within one imaging session, with increased patient as well as referrer convenience. The aim of this pilot study was to investigate this matter for the first time.
Methods
100 subjects (age 70 ± 10 yrs, 46 female), n = 51 with clinically defined mild cognitive impairment (MCI), n = 44 with possible/probable AD dementia, and n = 5 with frontotemporal lobe degeneration, underwent simultaneous [
18
F]florbetaben or [
11
C]PIB PET/MRI (3 Tesla Siemens mMR). Brain amyloid load, mesial temporal lobe atrophy (MTLA) by means of the Scheltens scale, and other morphological brain pathologies were scored by respective experts. The patients/caregivers as well as the referrers were asked to assess on a five-point scale the convenience related to the one-stop-shop PET and MRI approach.
Results
In three subjects, MRI revealed temporal lobe abnormalities other than MTLA. According to the National Institute on Aging-Alzheimer’s Association classification, the combined amyloid-beta PET/MRI evaluation resulted in 31 %, 45 %, and 24 % of the MCI subjects being categorized as “MCI-unlikely due to AD”, “MCI due to AD-intermediate likelihood”, and “MCI due to AD-high likelihood”, respectively. 50 % of the probable AD dementia patients were categorized as “High level of evidence of AD pathophysiological process”, and 56 % of the possible AD dementia patients as “Possible AD dementia - with evidence of AD pathophysiological process”. With regard to the International Working Group 2 classification, 36 subjects had both positive diagnostic and progression biomarkers. The patient/caregiver survey revealed a gain of convenience in 88 % of responders as compared to a theoretically separate PET and MR imaging. In the referrer survey, an influence of the combined amyloid-beta PET/MRI on the final diagnosis was reported by 82 % of responders, with a referrer acceptance score of 3.7 ± 1.0 on a 5-point scale.
Conclusion
Simultaneous amyloid PET/MRI is feasible and provides imaging biomarkers of all categories which are able to supplement the clinical diagnosis of MCI due to AD and that of AD dementia. Further, patient and referrer convenience is improved by this one-stop-shop imaging approach.</description><subject>Aged</subject><subject>Alzheimer Disease - diagnostic imaging</subject><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer's disease</subject><subject>Amyloid - metabolism</subject><subject>Attitude of Health Personnel</subject><subject>Biomarkers - metabolism</subject><subject>Cardiology</subject><subject>Cognitive Dysfunction - diagnostic imaging</subject><subject>Cognitive Dysfunction - metabolism</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Image Enhancement - methods</subject><subject>Imaging</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Molecular Imaging - methods</subject><subject>Multimodal Imaging - methods</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Pathology</subject><subject>Patient Acceptance of Health Care</subject><subject>Positron-Emission Tomography - methods</subject><subject>Radiology</subject><subject>Reproducibility of Results</subject><subject>Sensitivity and Specificity</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkV1LwzAUhoMobn78AG-k4I03dSdpPlrvZGw6mCgyr0OankpHP2azwvbvzegcIgheJSHPec8570vIFYU7CqBGDoCJJAQqw4hLFm6OyJBKmoQK4uT4cFcwIGfOLQFozOLklAyY4pGIpBqS-ykaV6RFWay3gamzwFiLq7WpLQZNHrii6kr_wqZzgam2ZVNkwetkMXp-m12Qk9yUDi_35zl5n04W46dw_vI4Gz_MQ8sVXYdWceAWJGUYI-bIUkltTpFzAVRhRBkVYBikuYwFMyZPhcgo56nJDEaZiM7Jba-7apvPDt1aV4WzWJb9WNovpRImZBL_B5WKJSpWHr35hS6brq39IjvKmyM86CnaU7ZtnGsx16u2qEy71RT0LgPdZ6B9BnqXgd74muu9cpdWmB0qvk33AOsB57_qD2x_tP5T9QutsI_S</recordid><startdate>20161101</startdate><enddate>20161101</enddate><creator>Schütz, Lisa</creator><creator>Lobsien, Donald</creator><creator>Fritzsch, Dominik</creator><creator>Tiepolt, Solveig</creator><creator>Werner, Peter</creator><creator>Schroeter, Matthias L.</creator><creator>Berrouschot, Jörg</creator><creator>Saur, Dorothee</creator><creator>Hesse, Swen</creator><creator>Jochimsen, Thies</creator><creator>Rullmann, Michael</creator><creator>Sattler, Bernhard</creator><creator>Patt, Marianne</creator><creator>Gertz, Hermann-Josef</creator><creator>Villringer, Arno</creator><creator>Claßen, Joseph</creator><creator>Hoffmann, Karl-Titus</creator><creator>Sabri, Osama</creator><creator>Barthel, Henryk</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20161101</creationdate><title>Feasibility and acceptance of simultaneous amyloid PET/MRI</title><author>Schütz, Lisa ; Lobsien, Donald ; Fritzsch, Dominik ; Tiepolt, Solveig ; Werner, Peter ; Schroeter, Matthias L. ; Berrouschot, Jörg ; Saur, Dorothee ; Hesse, Swen ; Jochimsen, Thies ; Rullmann, Michael ; Sattler, Bernhard ; Patt, Marianne ; Gertz, Hermann-Josef ; Villringer, Arno ; Claßen, Joseph ; Hoffmann, Karl-Titus ; Sabri, Osama ; Barthel, Henryk</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-c7404c0612e8eefe2b61cf1e445017e312150a20bf6852aafb55d144badae3d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Alzheimer Disease - diagnostic imaging</topic><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer's disease</topic><topic>Amyloid - metabolism</topic><topic>Attitude of Health Personnel</topic><topic>Biomarkers - metabolism</topic><topic>Cardiology</topic><topic>Cognitive Dysfunction - diagnostic imaging</topic><topic>Cognitive Dysfunction - metabolism</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Image Enhancement - methods</topic><topic>Imaging</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Molecular Imaging - methods</topic><topic>Multimodal Imaging - methods</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Pathology</topic><topic>Patient Acceptance of Health Care</topic><topic>Positron-Emission Tomography - methods</topic><topic>Radiology</topic><topic>Reproducibility of Results</topic><topic>Sensitivity and Specificity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schütz, Lisa</creatorcontrib><creatorcontrib>Lobsien, Donald</creatorcontrib><creatorcontrib>Fritzsch, Dominik</creatorcontrib><creatorcontrib>Tiepolt, Solveig</creatorcontrib><creatorcontrib>Werner, Peter</creatorcontrib><creatorcontrib>Schroeter, Matthias L.</creatorcontrib><creatorcontrib>Berrouschot, Jörg</creatorcontrib><creatorcontrib>Saur, Dorothee</creatorcontrib><creatorcontrib>Hesse, Swen</creatorcontrib><creatorcontrib>Jochimsen, Thies</creatorcontrib><creatorcontrib>Rullmann, Michael</creatorcontrib><creatorcontrib>Sattler, Bernhard</creatorcontrib><creatorcontrib>Patt, Marianne</creatorcontrib><creatorcontrib>Gertz, Hermann-Josef</creatorcontrib><creatorcontrib>Villringer, Arno</creatorcontrib><creatorcontrib>Claßen, Joseph</creatorcontrib><creatorcontrib>Hoffmann, Karl-Titus</creatorcontrib><creatorcontrib>Sabri, Osama</creatorcontrib><creatorcontrib>Barthel, Henryk</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schütz, Lisa</au><au>Lobsien, Donald</au><au>Fritzsch, Dominik</au><au>Tiepolt, Solveig</au><au>Werner, Peter</au><au>Schroeter, Matthias L.</au><au>Berrouschot, Jörg</au><au>Saur, Dorothee</au><au>Hesse, Swen</au><au>Jochimsen, Thies</au><au>Rullmann, Michael</au><au>Sattler, Bernhard</au><au>Patt, Marianne</au><au>Gertz, Hermann-Josef</au><au>Villringer, Arno</au><au>Claßen, Joseph</au><au>Hoffmann, Karl-Titus</au><au>Sabri, Osama</au><au>Barthel, Henryk</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Feasibility and acceptance of simultaneous amyloid PET/MRI</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2016-11-01</date><risdate>2016</risdate><volume>43</volume><issue>12</issue><spage>2236</spage><epage>2243</epage><pages>2236-2243</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose
Established Alzheimer’s disease (AD) biomarker concepts classify into amyloid pathology and neuronal injury biomarkers, while recent alternative concepts classify into diagnostic and progression AD biomarkers. However, combined amyloid positron emission tomography/magnetic resonance imaging (PET/MRI) offers the chance to obtain both biomarker category read-outs within one imaging session, with increased patient as well as referrer convenience. The aim of this pilot study was to investigate this matter for the first time.
Methods
100 subjects (age 70 ± 10 yrs, 46 female), n = 51 with clinically defined mild cognitive impairment (MCI), n = 44 with possible/probable AD dementia, and n = 5 with frontotemporal lobe degeneration, underwent simultaneous [
18
F]florbetaben or [
11
C]PIB PET/MRI (3 Tesla Siemens mMR). Brain amyloid load, mesial temporal lobe atrophy (MTLA) by means of the Scheltens scale, and other morphological brain pathologies were scored by respective experts. The patients/caregivers as well as the referrers were asked to assess on a five-point scale the convenience related to the one-stop-shop PET and MRI approach.
Results
In three subjects, MRI revealed temporal lobe abnormalities other than MTLA. According to the National Institute on Aging-Alzheimer’s Association classification, the combined amyloid-beta PET/MRI evaluation resulted in 31 %, 45 %, and 24 % of the MCI subjects being categorized as “MCI-unlikely due to AD”, “MCI due to AD-intermediate likelihood”, and “MCI due to AD-high likelihood”, respectively. 50 % of the probable AD dementia patients were categorized as “High level of evidence of AD pathophysiological process”, and 56 % of the possible AD dementia patients as “Possible AD dementia - with evidence of AD pathophysiological process”. With regard to the International Working Group 2 classification, 36 subjects had both positive diagnostic and progression biomarkers. The patient/caregiver survey revealed a gain of convenience in 88 % of responders as compared to a theoretically separate PET and MR imaging. In the referrer survey, an influence of the combined amyloid-beta PET/MRI on the final diagnosis was reported by 82 % of responders, with a referrer acceptance score of 3.7 ± 1.0 on a 5-point scale.
Conclusion
Simultaneous amyloid PET/MRI is feasible and provides imaging biomarkers of all categories which are able to supplement the clinical diagnosis of MCI due to AD and that of AD dementia. Further, patient and referrer convenience is improved by this one-stop-shop imaging approach.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>27435367</pmid><doi>10.1007/s00259-016-3462-x</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2016-11, Vol.43 (12), p.2236-2243 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1827925698 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aged Alzheimer Disease - diagnostic imaging Alzheimer Disease - metabolism Alzheimer's disease Amyloid - metabolism Attitude of Health Personnel Biomarkers - metabolism Cardiology Cognitive Dysfunction - diagnostic imaging Cognitive Dysfunction - metabolism Feasibility Studies Female Humans Image Enhancement - methods Imaging Magnetic Resonance Imaging - methods Male Medical imaging Medicine Medicine & Public Health Molecular Imaging - methods Multimodal Imaging - methods Nuclear Medicine Oncology Original Article Orthopedics Pathology Patient Acceptance of Health Care Positron-Emission Tomography - methods Radiology Reproducibility of Results Sensitivity and Specificity |
| title | Feasibility and acceptance of simultaneous amyloid PET/MRI |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T19%3A22%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Feasibility%20and%20acceptance%20of%20simultaneous%20amyloid%20PET/MRI&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Sch%C3%BCtz,%20Lisa&rft.date=2016-11-01&rft.volume=43&rft.issue=12&rft.spage=2236&rft.epage=2243&rft.pages=2236-2243&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-016-3462-x&rft_dat=%3Cproquest_cross%3E1826729787%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1825365729&rft_id=info:pmid/27435367&rfr_iscdi=true |